WO 2005/019236

- 40 -

PCT/AU2004/001110

## Claims:

## 1. A compound of general formula (I):

$$X_3$$
 $X_3$ 
 $X_2$ 
 $X_2$ 
 $X_3$ 
 $X_4$ 
 $X_5$ 
 $X_5$ 

5

25

wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of hydrogen, optionally substituted 10 alkyl which may be interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=,  $NR_7$  and  $-(Y)_mC=(Z)(T)_n-$ , optionally substituted alkenyl which may be interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR<sub>7</sub> and -(Y)<sub>m</sub>C=(Z)(T)<sub>n</sub>-, 15 optionally substituted aralkyl which may be interrupted within the alkyl moiety by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR<sub>7</sub> and -(Y)<sub>m</sub>C=(Z)(T)<sub>n</sub>-, optionally substituted heterocyclic, optionally substituted aryl, optionally 20 substituted acyl and a carbohydrate moiety;

or  $R_1$  and  $R_2$  together with the nitrogen atom from which they depend form a saturated or unsaturated, optionally substituted heterocyclic group which may include additional heteroatoms selected from the group consisting of O, N and S;

A is selected from the group consisting of O, S, SO, SO<sub>2</sub>, Se, Te, NR<sub>8</sub>,  $CR_9R'_9$ , N->O and C(O);

 $X_1$  is selected from the group consisting of  $OR_3$ ,  $SR_3$ ,  $NR_3R'_3$ , hydrogen, halogen,  $-(Y)_mC=(Z)(T)_nR_3$ ,  $-N(C=(Z)(T)_nR_3)_2$ ,  $N_3$ , CN, OCN, SCN,  $OSO_3R_3$ ,  $OSO_2R_3$ ,  $OPO_3R_3R'_3$ ,  $OPO_2R_3R'_3$ ,  $S(O)_2R_3$ ,  $S(O)_2OR_3$ ,  $PO_3R_3R'_3$ ,  $NR_3NR'_3R''_3$ ,  $SNR_3R'_3$ ,  $NR_3SR'_3$ ,  $SSR_3$  and  $R_3$ , or is an oxo group, =S,  $=NOR_3$  or  $=CR_3R'_3$  and  $X_1'$  is absent, or  $X_1$  is C=(Z) and  $R_2$  is

25

30

35

bonded thereto so as to form a cyclic moiety -  $C=(Z)NR_1S(O)_p-$ ;

 $X_2$  is selected from the group consisting of  $OR_4$ ,  $SR_4$ ,  $NR_4R'_4$ , hydrogen, halogen,  $-(Y)_mC=(Z)(T)_nR_4$ ,  $-N(C=(Z)(T)_nR_4)_2$ ,  $N_3$ , CN, OCN, SCN,  $OSO_3R_4$ ,  $OSO_2R_4$ ,  $OPO_3R_4R'_4$ ,  $OPO_2R_4R'_4$ ,  $S(O)_2R_4$ ,  $S(O)_2R_4$ ,  $S(O)_2OR_4$ ,  $PO_3R_4R'_4$ ,  $NR_4NR'_4R''_4$ ,  $SNR_4R'_4$ ,  $NR_4SR'_4$ ,  $SSR_4$  and  $R_4$ , or is an oxo group, =S,  $=NOR_4$  or  $=CR_4R'_4$  and  $X_2$ ' is absent;

 $X_3$  and  $X_3$ 'are independently selected from the group consisting of  $OR_5$ ,  $SR_5$ ,  $NR_5R'_5$ , hydrogen, halogen, -  $(Y)_mC=(Z)(T)_nR_5$ ,  $-N(C=(Z)(T)_nR_5)_2$ ,  $N_3$ , CN, OCN, SCN,  $OSO_3R_5$ ,  $OSO_2R_5$ ,  $OPO_3R_5R'_5$ ,  $OPO_2R_5R'_5$ ,  $S(O)R_5$ ,  $S(O)_2R_5$ ,  $S(O)_2OR_5$ ,  $PO_3R_5R'_5$ ,  $NR_5NR'_5R''_5$ ,  $SNR_5R'_5$ ,  $NR_5SR'_5$ ,  $SSR_5$  and  $R_5$ , or  $X_3$  is an oxo group, =S,  $=NOR_5$  or  $=CR_5R'_5$  and  $X_3$ ' is absent;

15  $X_4$  is selected from the group consisting of  $OR_6$ ,  $SR_6$ ,  $NR_6R'_6$ , hydrogen, halogen,  $-(Y)_mC=(Z)(T)_nR_6$ ,  $-N(C=(Z)(T)_nR_6)_2$ ,  $N_3$ , CN, OCN, SCN,  $OSO_3R_6$ ,  $OSO_2R_6$ ,  $OPO_3R_6R'_6$ ,  $OPO_2R_6R'_6$ ,  $S(O)_2R_6$ ,  $S(O)_2OR_6$ ,  $PO_3R_6R'_6$ ,  $NR_6NR'_6R''_6$ ,  $SNR_6R'_6$ ,  $NR_6SR'_6$ ,  $SSR_6$  and  $R_6$ , or is an oxo group, =S,  $=NOR_6$  or  $=CR_6R'_6$  and  $X_4$ ' is absent;

 $X_5$  is selected from the group consisting of hydrogen, CN,  $-C=(Z)(T)_nR_{11}$ ,  $S(O)R_{11}$ ,  $S(O)_2R_{11}$ ,  $S(O)_2OR_{11}$ ,  $PO_3R_{11}R'_{11}$ , optionally substituted alkyl, optionally substituted aryl, optionally substituted aryl, optionally substituted aryl, and optionally substituted acyl;

 $X_1$ ',  $X_2$ ',  $X_4$ ' and  $X_5$ ' are the same or different and are selected from the group consisting of hydrogen, CN, optionally substituted alkyl, optionally substituted alkaryl, optionally substituted aryl, optionally substituted acyl;

or one of  $X_1$  and  $X_2$ ,  $X_2$  and  $X_5$ ,  $X_5$ , and A when A contains a carbon or nitrogen atom,  $X_5$  and A when A contains a carbon or nitrogen atom, and  $X_5$  and  $X_1$  together constitute a double bond, or  $X_5$ , and  $X_4$  or  $X_3$  and  $X_4$  together constitute a double bond, or  $X_1$  and  $X_2$ ,  $X_2$  and  $X_3$ ,  $X_4$  and  $X_5$ ,  $X_5$ ,  $X_6$  and  $X_7$ ,  $X_8$ , and  $X_8$ ,  $X_8$ ,  $X_8$ , and  $X_8$ ,  $X_8$ ,  $X_8$ , and  $X_$ 

 $X_2$  and  $X_2'$ ,  $X_3$  and  $X_3'$  or  $X_4$  and  $X_4'$  together form part of a ring structure which optionally includes at least one heteroatom selected from O, S and N and is optionally substituted;

m and n are independently zero or one and Y, Z and T are independently selected from the group consisting of O, S, and  $NR_{10}$ 

p is 1 or 2

q is 0 or 1;

 $R_3$ ,  $R'_3$ ,  $R''_3$ ,  $R_4$ ,  $R'_4$ ,  $R''_4$ ,  $R_5$ ,  $R'_5$ ,  $R''_5$ ,  $R_6$ ,  $R'_6$ , 10  $R''_{6}$ ,  $R_{7}$ ,  $R_{8}$ ,  $R_{9}$ ,  $R'_{9}$ ,  $R_{10}$ ,  $R_{11}$  and  $R'_{11}$  are the same or different and are selected from the group consisting of hydrogen, optionally substituted alkyl which may be interrupted by one or more heteroatoms or functional 15 groups selected from the group consisting of O, S, -N=, NR7 and  $-(Y)_{m}C=(Z)(T)_{n}-$ , optionally substituted alkenyl which may be interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR<sub>7</sub> and -(Y)<sub>m</sub>C=(Z)(T)<sub>n</sub>-, optionally substituted aryl, optionally substituted heterocyclic, optionally 20 substituted aralkyl which may be interrupted within the alkyl moiety by one or more heteroatoms or functional groups selected from the group consisting of 0, S, -N=,  $NR_7$ and  $-(Y)_mC=(Z)(T)_{n-}$ , optionally substituted acyl and a carbohydrate moiety; 25

with the proviso that at least two of  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are other than hydrogen or a group linked to the ring through a carbon-carbon bond; or a pharmaceutically acceptable salt thereof.

- 30 2. A compound as claimed in claim 1 wherein one or both of  $R_1$  and  $R_2$  is alkyl.
  - 3. A compound as claimed in claim 2 wherein one or both of  $R_1$  and  $R_2$  is  $C_{4-30}$  alkyl.
- 4. A compound as claimed in claim 3 wherein one or 35 both of  $R_1$  and  $R_2$  is  $C_{6-12}$  alkyl.
  - 5. A compound as claimed in claim 4 wherein one or both of  $R_1$  and  $R_2$  is  $C_{8-10}$  alkyl.
    - 6. A compound as claimed in claim 1 wherein one or

5

15

20

both or  $R_1$  and  $R_2$  is aralkyl.

- 7. A compound as claimed in claim 6 wherein one or both  $R_1$  and  $R_2$  is  $(CH_2)_rPh$  where Ph is phenyl and Ph is an integer in the range 1 to 12 inclusive.
- 8. A compound as claimed in claim 1 wherein one or both of  $R_1$  and  $R_2$  is alkyl interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR<sub>7</sub>, and -(Y)<sub>m</sub>C=(Z)(T)<sub>n</sub>.
- 9. A compound as claimed in claim 8 wherein one or 10 both of  $R_1$  and  $R_2$  is alkyl interrupted by one or more oxygen atoms.
  - 10. A compound as claimed in claim 9 wherein one or both of  $R_1$  and  $R_2$  is  $CH_3(CH_2)_xO(CH_2)_yO(CH_2)_z$  wherein x is an integer in the range 0 to 12 inclusive and y and z are independently integers in the range 1 to 12 inclusive.
  - 11. A compound as claimed in claim 1 wherein one or both of  $R_1$  and  $R_2$  is alkenyl.
  - 12. A compound as claimed in claim 1 wherein  $R_1$  and  $R_2$  together with the nitrogen atom from which they depend form a saturated or unsaturated heterocyclic group.
  - 13. A compound as claimed in claim 1 wherein  $R_1$  and  $R_2$  together with the nitrogen atom from which they depend form a lactam or cyclic imide.
- 14. A compound as claimed in any one of claims 1 to 25 13 wherein q is 1.
  - 15. A compound as claimed in any one of claims 1 to 13 wherein q is 0.
- 16. A compound as claimed in any one of claims 1 to 15 wherein A is selected from the group consisting of 0, S and  $NR_8$ .
  - 17. A compound as claimed in claim 16 wherein A is O.
  - 18. A compound as claimed in any one of claims 1 to 17 wherein  $X_1$  is  $OR_3$ .
- 19. A compound as claimed in claim 18 wherein  $R_3$  is hydrogen or optionally substituted acyl.
  - 20. A compound as claimed in any one of claims 1 to 19 wherein  $X_2$  is  $OR_4$ .

20

30

35

- 21. A compound as claimed in claim 20 wherein  $R_4$  is hydrogen or optionally substituted acyl.
- 22. A compound as claimed in any one of claims 1 to 21 wherein  $X_3$  is  $OR_5$ .
- 5 23. A compound as claimed in claim 22 wherein  $R_5$  is hydrogen or optionally substituted acyl.
  - 24. A compound as claimed in any one of claims 1 to 14 and 16 to 23 wherein  $X_4$  is  $OR_6$ .
- 25. A compound as claimed in claim 24 wherein  $R_6$  is 10 hydrogen or optionally substituted acyl.
  - 26. A compound as claimed in any one of claims 1 to 25 wherein p is 1.
  - 27. A compound as claimed in any one of claims 1 to 25 wherein p is 2.
- 28. A compound selected from the group consisting of:
  - N, N-dibuty1-S-(2,3,5,6-tetra-O-benzoy1- $\beta$ -D-galactofuranosy1) sulfonamide
  - N, N-dihexyl-S-(2,3,5,6-tetra-O-acetyl- $\beta$ -D-galactofuranosyl) sulfonamide
  - N, N-dioctyl-S-(2,3,5,6-tetra-O-benzoyl- $\beta$ -D-galactofuranosyl) sulfonamide
  - N, N-didecyl-S-(2,3,5,6-tetra-O-acetyl- $\beta$ -D-galactofuranosyl) sulfonamide
- 25  $N, N-dibenzyl-S-(2,3,5,6-tetra-O-benzoyl-\beta-D-galactofuranosyl)$  sulfonamide
  - N,N-di(2-methoxyethoxyethyl)-S-(2,3,5,6-tetra-0-acetyl- $\beta$ -D-galactofuranosyl) sulfonamide
  - N, N-dioctyl-S-(2,3,5,6-tetra-O-acetyl- $\beta$ -D-glucofuranosyl) sulfonamide
  - N, N-dioctyl-S-(2,3-di-O-acetyl-5-0-[tert-butyldiphenylsilyl]- $\alpha$ -D-arabinofuranosyl) sulfonamide
    - N, N-dibutyl-S- $(\beta$ -D-galactofuranosyl) sulfonamide
      - N, N-dihexyl-S- $(\beta$ -D-galactofuranosyl) sulfonamide
    - N, N-dioctyl-S-( $\beta$ -D-galactofuranosyl) sulfonamide
      - N, N-didecyl-S- $(\beta$ -D-galactofuranosyl) sulfonamide
      - N, N-dibenzyl-S- $(\beta$ -D-galactofuranosyl) sulfonamide
      - N, N-di (2-methoxyethoxyethyl) -S- ( $\beta$ -D-

WO 2005/019236 PCT/AU2004/001110

- 45 -

galactofuranosyl) sulfonamide

N, N-dioctyl-S-( $\beta$ -D-glucofuranosyl) sulfonamide

29. A method of preparation of a compound of general formula (I)

5

$$X_3$$
 $X_2$ 
 $X_2$ 
 $X_1$ 
 $X_2$ 
 $X_1$ 
 $X_2$ 
 $X_2$ 
 $X_1$ 
 $X_2$ 
 $X_1$ 
 $X_2$ 
 $X_2$ 
 $X_2$ 
 $X_3$ 

comprising reacting a compound of general formula (II):

$$X_3$$
  $X_2$   $X_2$   $X_3$   $X_4$   $X_5$   $X_5$   $X_5$   $X_5$   $X_5$   $X_1$   $X_1$   $X_2$   $X_2$   $X_2$   $X_3$   $X_4$   $X_5$   $X_5$   $X_5$   $X_5$   $X_7$   $X_8$ 

10

wherein  $R_1$ ,  $R_2$ , A, p, q,  $X_1$ ,  $X_2$ ,  $X_2$ ,  $X_2$ ,  $X_3$ ,  $X_3$ ,  $X_4$ ,  $X_4$ ,  $X_5$  and  $X_5$  are as defined above;

with an oxidising agent.

- 30. A method for the treatment of a microbial infection comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of general formula (I) as claimed in any one of claims 1 to 28.
- 31. The use of a compound of general formula (I) as
  20 claimed in any one of claims 1 to 28 in the manufacture of
  a medicament for use in the treatment of a microbial
  infection.
  - 32. A pharmaceutical composition comprising a compound of general formula (I) as claimed in any one of claims 1 to 28 and a pharmaceutically acceptable carrier.
  - 33. A method of killing a microorganism, comprising exposing said microorganism to a compound of general formula (I) as claimed in any one of claims 1 to 28.

25